CSBR / Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates

HACKENSACK, NJ / ACCESSWIRE / July 20, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug d more_horizontal

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200% and 2.26%, respectively, for the quarter ended January 2023. Do the more_horizontal

CSBR runs a PDX bank. PDXs are mice models of human derived tumors. The company offers services to bio and pharma companies in pre clinical treatment more_horizontal

Champions Oncology, Inc. (NASDAQ:CSBR ) Q2 2023 Results Conference Call December 13, 2022 4:30 PM ET Company Participants Ronnie Morris - CEO David Mi more_horizontal

HACKENSACK, NJ / ACCESSWIRE / December 9, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming dru more_horizontal

Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2023 Earnings Conference Call September 8, 2022 4:30 PM ET Company Participants Ronnie Morris - CEO David M more_horizontal

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -300% and 2.27%, respectively, for the quarter ended July 2022. Do the num more_horizontal

Here is how Champions Oncology, Inc. (CSBR) and Gamida Cell (GMDA) have performed compared to their sector so far this year. more_horizontal